Anthony Altobelli, MD
Cardiovascular Disease · East Brunswick, NJNPI 1003843905
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $123,720 of the $137,343 with a category attached, or 90.1%. 37 manufacturers reported payments, led by Boehringer Ingelheim at 38.4% of the total. Reporting peaked in 2024 at $34,164 and has fallen 72.2% since, to $9,497 in 2025. Among cardiovascular disease clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 618 payments — averaging $222.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$53K
- Esperion Therapeutics, Inc.$44K
- Lilly USA, LLC$17K
- Johnson & Johnson$11K
- Novartis$8K
- Impulse Dynamics (USA) Inc.$1K
- plus $4K from 31 others
What the payments were for
- Consulting fees$5000%
- Speaking & faculty fees$123,72090%
- Travel & lodging$2,1312%
- Food & beverage$10,9938%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 106 | $52,796 |
| Esperion Therapeutics, Inc. | 76 | $44,192 |
| Lilly USA, LLC | 25 | $16,969 |
| Johnson & Johnson | 108 | $10,583 |
| Novartis | 143 | $7,889 |
| Impulse Dynamics (USA) Inc. | 11 | $1,043 |
| Amgen | 32 | $444 |
| Abbott | 4 | $441 |
| Boston Scientific | 10 | $386 |
| Abiomed | 3 | $285 |
| AstraZeneca | 10 | $260 |
| E.r. Squibb & Sons, L.L.C. | 16 | $247 |
| Ancora Heart, Inc. | 4 | $246 |
| Edwards Lifesciences | 1 | $204 |
| Merck | 11 | $166 |
| Pfizer | 8 | $131 |
| Biosense Webster, Inc. | 2 | $114 |
| Bridgebio Pharma, Inc. | 5 | $90 |
| Cardiva Medical, Inc. | 1 | $89 |
| Medtronic | 2 | $86 |
| Alnylam Pharmaceuticals Inc. | 5 | $85 |
| Biotronik Inc. | 2 | $70 |
| Gilead | 5 | $67 |
| Daiichi Sankyo Inc. | 4 | $65 |
| Arbor Pharmaceuticals, Inc. | 4 | $63 |
| Novo Nordisk | 3 | $56 |
| Amarin Pharma, Inc. | 3 | $42 |
| Heartflow, Inc. | 2 | $41 |
| Atricure, Inc. | 2 | $38 |
| Jazz Pharmaceuticals Inc. | 2 | $29 |
| Cvrx, Inc. | 1 | $29 |
| Bayer | 2 | $28 |
| Tactile Systems Technology Inc | 1 | $16 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $15 |
| Altathera Pharmaceuticals LLC | 1 | $14 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $13 |
| Sanofi-aventis U.S. LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$68,487
- NEXLIZET$43,626
- NEXLETOL$43,626
- XARELTO$9,594
- ENTRESTO$7,069
- OPTIMIZER SMART SYSTEM$747
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$281
- Impella$256
- SAPIEN 3 Ultra RESILIA$204
- AccuCinch$163
- WATCHMAN FLX$137
- MitraClip$135
- WAINUA$125
- GENERAL - THERAPIES$102
How this compares
$137,343 in reported general payments places this provider in the 95th percentile of 1,006 cardiovascular disease providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 311 | $395,103 |
| XareltoRivaroxaban | 135 | $189,114 |
| EntrestoSacubitril/Valsartan | 122 | $187,744 |
| JardianceEmpagliflozin | 48 | $67,486 |
| FarxigaDapagliflozin Propanediol | 27 | $32,723 |
| MultaqDronedarone Hcl | 11 | $25,037 |
| Repatha SureclickEvolocumab | 30 | $22,056 |
| NexletolBempedoic Acid | 18 | $20,383 |
| BrilintaTicagrelor | 22 | $18,954 |
| LivaloPitavastatin Calcium | 19 | $12,964 |
| NexlizetBempedoic Acid/Ezetimibe | 14 | $12,092 |
| Metoprolol Succinate | 607 | $9,138 |
| Atorvastatin Calcium | 721 | $8,648 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 23 | $8,388 |
| Icosapent Ethyl | 13 | $8,092 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $131 | $395,103311 claims |
| Johnson & JohnsonXarelto | $10,583 | $189,114135 claims |
| NovartisEntresto | $7,889 | $187,744122 claims |
| Boehringer IngelheimJardiance | $52,796 | $67,48648 claims |
| AstraZenecaFarxiga, Brilinta | $260 | $51,67749 claims |
| Esperion Therapeutics, Inc.Nexletol, Nexlizet | $44,192 | $32,47532 claims |
| Sanofi-aventis U.S. LLCMultaq | $12 | $25,03711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,006 cardiovascular disease providers in New Jersey.
Other cardiovascular disease in East Brunswick
- David SchaerEast Brunswick$75K
- Marc CohenNewark$762K
- Peter FarrugiaColts Neck$600K
- Felix Dailey-SterlingGuttenberg$568K
- Ramzan ZakirNew Brunswick$342K
- Richard KovachBrowns Mills$300K
- Andrea RussoCamden$293K
- John KostisNew Brunswick$225K
- Dilip ViswanathHaddon Heights$167K
- David PowellSpringfield$162K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.